Monitoring tissue coagulation during thermoablative treatment by using a novel magnetic resonance imaging contrast agent.
BACKGROUND
We tested the feasibility of using a novel contrast agent, MS-325, as a marker of coagulating tissue during thermoablative treatment.


METHODS
In vivo, we created coagulated lesions in porcine muscle tissue under 3 different conditions: MS-325 (n = 5), gadolinium-DTPA (n = 5), or no contrast agent (n = 9) present during laser thermoablation. At the same time, we performed continuous T1-weighted magnetic resonance imaging at 1.5 T. We quantified the change in signal intensity during treatment expressed as relative enhancement, and compared the 3 groups by using Mann-Whitney analysis.


RESULTS
MS-325 resulted in a more than 3.2-fold increase in relative enhancement over the gadolinium-DTPA and noncontrast control groups (P < 0.008).


CONCLUSIONS
MS-325 appears to be a valid marker for coagulating tissue and significantly increased relative enhancement of the treated lesions when compared with both Gd-DTPA and noncontrast-enhanced conditions. MS-325 thus has potential for monitoring of thermoablative treatment.
Department of Radiology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
Mika W
MW
Vogel
Cornelius A C
CA
Entius
Peter M T
PM
Pattynama
D000818:Animals; D003287:Contrast Media; D005240:Feasibility Studies; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006979:Hyperthermia, Induced; D008279:Magnetic Resonance Imaging / Q000379:methods*; D018482:Muscle, Skeletal; D009942:Organometallic Compounds; D018709:Statistics, Nonparametric; D013552:Swine
D003287:Contrast Media; D009942:Organometallic Compounds; D005682:Gadolinium; D019786:Gadolinium DTPA; C109932:gadofosveset trisodium